BamSEC and AlphaSense Join Forces
Learn More

Generate Biomedicines Inc. – Material Contracts

NASDAQ: GENB    
Share price (6/3/26): $12.91    
Market cap (6/3/26): $1.655 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.8
from S-1/A 7 pages Generate Biomedicines, Inc. Compensation Recovery Policy Adopted February 18, 2026
12/34/56
EX-10.7
from S-1/A 4 pages Generate Biomedicines, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.6
from S-1/A 17 pages Therefore, the Board Has Adopted This Plan to Reinforce and Encourage the Continued Attention and Dedication of the Covered Executives to Their Assigned Duties Without Distraction. This Plan Contains Information That Will Help Covered Executives Understand the Severance Pay and Benefits Being Offered Hereunder. the Company Encourages All Covered Executives to Read the Plan Carefully. Note That Capitalized Words and Phrases Used Throughout This Document Are Generally Defined in Section 4. if You Have Any Questions Regarding the Plan, Please Contact Peopleoperations@generatebiomedicines.com. 2. Establishment of Plan
12/34/56
EX-10.5
from S-1/A 4 pages This Senior Executive Cash Incentive Bonus Plan (The “Incentive Plan”) Is Intended to Provide an Incentive for Superior Work and to Motivate Eligible Executives of Generate Biomedicines, Inc. (The “Company”) and Its Affiliates Toward Even Higher Achievement and Business Results, to Tie Their Goals and Interests to Those of the Company and Its Stockholders and to Enable the Company to Attract and Retain Highly Qualified Executives. the Incentive Plan Is for the Benefit of Covered Executives (As Defined Below). 2. Covered Executives
12/34/56
EX-10.4
from S-1/A 35 pages Generate Biomedicines, Inc. Indemnification Agreement
12/34/56
EX-10.3
from S-1/A 11 pages Generate Biomedicines, Inc. 2026 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 35 pages Generate Biomedicines, Inc. 2026 Equity Incentive Plan
12/34/56
EX-10.1
from S-1/A 18 pages Generate Biomedicines, Inc. 2019 Equity Incentive Plan Updated as of February 21, 2025
12/34/56
EX-10.18
from S-1/A 34 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. Development and Manufacturing Services Agreement Between Lonza Sales AG and Lonza AG and Generate Biomedicines Inc. 1
12/34/56
EX-10.17
from S-1/A 66 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. Stock Purchase Agreement by and Among Generate Biomedicines, Inc., Pioneering Medicines 02, Inc., Pioneering Medicines 02, LLC, and Flagship Labs, LLC Dated as of February 4, 2026 Stock Purchase Agreement
12/34/56
EX-10.12
from S-1/A 25 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. Licence Agreement Between Lonza Sales AG and Generate Biomedicines, Inc. 1 Index
12/34/56
EX-10.11
from S-1/A 28 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. License Agreement
12/34/56
EX-10.16
from S-1 67 pages Lease Agreement by and Between Iqhq-4 Corporate, LLC, a Delaware Limited Liability Company, as Landlord, and Generate Biomedicines, Inc. a Delaware Corporation, as Tenant Innovation Park, 4 Corporate Drive, Andover, Ma
12/34/56
EX-10.15
from S-1 153 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.14
from S-1 9 pages On Behalf of Generate Biomedicines, Inc. (The “Company”), a Flagship Pioneering Company, I Am Delighted to Make This Conditional Offer of Employment With the Company. This Offer Letter (The “Offer Letter”) and the Accompanying Documents and Agreements, Which Are Incorporated Herein, Summarize and Set Forth Important Terms About Your Employment With the Company. 1. Starting Date, Position, and Duties. A. Your Initial Position Shall Be Chief Financial Officer Reporting to Michael Nally. We Anticipate That Your Employment Shall Start Effective July 18th, 2022 (The Actual Date You Begin to Work for the Company, the “Start Date”). B
12/34/56
EX-10.13
from S-1 3 pages September 11, 2018 Gevorg Grigoryan [Omitted] Re: Employment by Flagship Vl56, Inc. Dear Gevorg
12/34/56
EX-10.10
from S-1 86 pages Collaboration Agreement Between Amgen Inc. and Generate Biomedicines, Inc. Collaboration Agreement
12/34/56
EX-10.9
from S-1 97 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. Collaboration and License Agreement by and Between Novartis Pharma AG and Generate Biomedicines, Inc. September 19, 2024
12/34/56
EX-10.1
from S-1 32 pages Generate Biomedicines, Inc. 2019 Equity Incentive Plan Updated as of February 19, 2024
12/34/56
EX-10.16
from DRS 67 pages Lease Agreement by and Between Iqhq-4 Corporate, LLC, a Delaware Limited Liability Company, as Landlord, and Generate Biomedicines, Inc. a Delaware Corporation, as Tenant Innovation Park, 4 Corporate Drive, Andover, Ma
12/34/56